Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2011
This article has no abstract
Epistemonikos ID: dbafdfa491e3b4a569fe9797fd616369dbc0662d
First added on: Feb 04, 2025